Priovant Therapeutics

Priovant Therapeutics’ lead asset, brepocitinib, an oral once-daily dual TYK2/JAK1 inhibitor, has demonstrated clinically meaningful efficacy in seven successful Phase 2 studies across multiple autoimmune diseases. The safety profile appears similar to approved JAK inhibitors. The VALOR Phase 3 trial in dermatomyositis has completed enrollment with top-line results expected in mid/late–2025. Positive topline results were announced from the NEPTUNE Phase 2 study of brepocitinib in non-infectious uveitis—the best observed efficacy data for this indication to date. A pivotal Phase 3 CLARITY study for NIU has been initiated. Additional indications such as cutaneous sarcoidosis are planned for future trials.